Background/Aims: The aim of this study was to evaluate patients’ outcomes, determine the prescriptions of continuous renal replacement therapy (CRRT) that effectively reduce serum ammonia levels, and analyze the prognostic factors in neonates with hyperammonemia. Methods: The medical records of 12 Korean neonates with inborn error of metabolism (IEM) who underwent CRRT for hyperammonemia were retrospectively analyzed. Results: All patients received continuous venovenous hemodiafiltration. The median ultrafiltration rate (UFR) at the initiation of CRRT was 2,288.4 mL/h/1.73 m2. The median ammonia level at CRRT initiation was 1,320 µmol/L, and the median time to reduce the initial ammonia level by at least 50% was 12.8 h. The survival rate during hospitalization was 83.3%. There were significant differences between patients with neurologic sequelae and those without poor outcomes in peak serum ammonia level before CRRT and serum ammonia level at CRRT initiation. Conclusion: This study suggested that CRRT could be a therapeutic option for neonates with IEM. However, it is necessary to raise the UFR above 4,000 mL/h/1.73 m2 in patients with high initial ammonia level.

Keywords:
Inborn error of metabolism, Hyperammonemia, Continuous renal replacement therapy, Newborn
1.
Auron A, Brophy PD: Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol 2012; 27: 207–222.
2.
Lanpher B, Brunetti-Pierri N, Lee B: Inborn errors of metabolism: the flux from Mendelian to complex diseases. Nat Rev Genet 2006; 7: 449–460.
3.
Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, Abeni D: Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr 2002; 140: 321–327.
4.
Cagnon L, Braissant O: Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res Rev 2007; 56: 183–197.
5.
Cooper AJ: Role of glutamine in cerebral nitrogen metabolism and ammonia neurotoxicity. Ment Retard Dev Disabil Res Rev 2001; 7: 280–286.
6.
van Rijt WJ, Koolhaas GD, Bekhof J, Heiner Fokkema MR, de Koning TJ, Visser G, Schielen PC, van Spronsen FJ, Derks TG: Inborn errors of metabolism that cause sudden infant death: a systematic review with implications for population neonatal screening programmes. Neonatology 2016; 109: 297–302.
7.
Leonard JV, Morris AA: Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatr 2006; 95: 6–14.
8.
Lindor NM, Karnes PS: Initial assessment of infants and children with suspected inborn errors of metabolism. Mayo Clin Proc 1995; 70: 987–988.
9.
Burton B: Inborn Errors of Metabolism in Infancy: A Guide to Diagnosis, 1999, p E69.
10.
Spinale JM, Laskin BL, Sondheimer N, Swartz SJ, Goldstein SL: High-dose continuous renal replacement therapy for neonatal hyperammonemia. Pediatr Nephrol 2013; 28: 983–986.
11.
Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M, Sabetta G, Rizzoni G, Bartuli A: Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol 2001; 16: 862–867.
12.
Bellomo R, Ronco C, Mehta RL: Nomenclature for continuous renal replacement therapies. Am J Kidney Dis 1996; 28:S2–S7.
13.
Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C: Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care 2016; 20: 318.
14.
Villa G, Neri M, Bellomo R, Cerda J, De Gaudio AR, De Rosa S, Garzotto F, Honore PM, Kellum J, Lorenzin A, Payen D, Ricci Z, Samoni S, Vincent JL, Wendon J, Zaccaria M, Ronco C: Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care 2016; 20: 283.
15.
Wong KY, Wong SN, Lam SY, Tam S, Tsoi NS: Ammonia clearance by peritoneal dialysis and continuous arteriovenous hemodiafiltration. Pediatr Nephrol 1998; 12: 589–591.
16.
Ogier de Baulny H: Management and emergency treatments of neonates with a suspicion of inborn errors of metabolism. Semin Neonatol 2002; 7: 17–26.
17.
Bunchman TE, Barletta GM, Winters JW, Gardner JJ, Crumb TL, McBryde KD: Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration. Pediatr Nephrol 2007; 22: 1062–1065.
18.
Kellum JA, Bellomo R, Ronco C: Kidney attack. JAMA 2012; 307: 2265–2266.
19.
Lameire NH, Flombaum CD, Moreau D, Ronco C: Acute renal failure in cancer patients. Ann Med 2005; 37: 13–25.
20.
McCullough PA, Bouchard J, Waikar SS, Siew ED, Endre ZH, Goldstein SL, Koyner JL, Macedo E, Doi K, Di Somma S, Lewington A, Thadhani R, Chakravarthi R, Ice C, Okusa MD, Duranteau J, Doran P, Yang L, Jaber BL, Meehan S, Kellum JA, Haase M, Murray PT, Cruz D, Maisel A, Bagshaw SM, Chawla LS, Mehta RL, Shaw AD, Ronco C: Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 5–12.
21.
Ronco C, Kellum JA, Haase M: Subclinical AKI is still AKI. Crit Care 2012; 16: 313.
22.
Ronco C, Ricci Z, De Backer D, Kellum JA, Taccone FS, Joannidis M, Pickkers P, Cantaluppi V, Turani F, Saudan P, Bellomo R, Joannes-Boyau O, Antonelli M, Payen D, Prowle JR, Vincent JL: Renal replacement therapy in acute kidney injury: controversy and consensus. Critical Care 2015; 19: 146.
23.
Hoste EA, Kellum JA, Katz NM, Rosner MH, Haase M, Ronco C: Epidemiology of acute kidney injury. Contrib Nephrol 2010; 165: 1–8.
24.
Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A: Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007; 356: 2282–2292.
25.
Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E: Dialysis in neonates with inborn errors of metabolism. Nephrol Dial Transplant 1999; 14: 910–918.
26.
Ricci Z, Ronco C, Bachetoni A, D'Amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P: Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10:R67.
27.
Arbeiter AK, Kranz B, Wingen AM, Bonzel KE, Dohna-Schwake C, Hanssler L, Neudorf U, Hoyer PF, Buscher R: Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism. Nephrol Dial Transplant 2010; 25: 1257–1265.
28.
Falk MC, Knight JF, Roy LP, Wilcken B, Schell DN, O’Connell AJ, Gillis J: Continuous venovenous haemofiltration in the acute treatment of inborn errors of metabolism. Pediatr Nephrol 1994; 8: 330–333.
29.
Parakininkas D, Greenbaum LA: Comparison of solute clearance in three modes of continuous renal replacement therapy. Pediatr Crit Care Med 2004; 5: 269–274.
30.
Ronco C, Bellomo R: Continuous renal replacement therapy: evolution in technology and current nomenclature. Kidney Int Suppl 1998; 66:S160–S164.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.